Recent FDA endorsements of gene therapy for treating spinal muscular dystrophy (SMA) and RPE65 mutation-associated retinal dystrophy offer the promise that a multitude of rare neurological disorders may soon find therapeutic avenues through gene therapy [22]. The gene discussed is RPE65; the disease is nervous system disorder.